UPCC 14426: Expanded Access Program for Mezigdomide (in combination with Carfilzomib/dex or Bortezomib/dex) For Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Enrolling By Invitation
99 years or below
All
Phase N/A
1 Location

Brief description of study

The purpose of this program is to be able to provide patients with the drug mezigdomide (CC-92480) for the treatment of multiple myeloma. The reason for treating patients using this program is because they fit one or more of the following criteria: 

        Patient has a serious or immediately life-threatening disease or condition.
        There is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition.
        Patient enrollment in a clinical trial is not possible.
        Potential patient benefit justifies the potential risks of treatment.
        Providing the investigational medical product will not interfere with investigational trials that could support a medical products development or marketing approval for the treatment indication

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 24 Aug 2026. Study ID: 26-6369
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator